Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review
Getz T, Bakirhan K, Seropian S, Shallis R. Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review. Annals Of Hematology 2025, 104: 3889-3892. PMID: 40576687, PMCID: PMC12334448, DOI: 10.1007/s00277-025-06388-w.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaT(8;21) acute myeloid leukemiaDeep remissionKIT mutationsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationCore binding factor acute myeloid leukemiaHematopoietic stem cell transplantationTreatment of acute myeloid leukemiaFavorable risk diseaseStem cell transplantationTyrosine kinase inhibitorsT(8;21)Based chemotherapyOverall survivalSystemic mastocytosisCell transplantationRisk diseaseTargeted therapyCase reportKinase inhibitorsClinical challengeT(8;21Clinical investigationAvapritinib
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply